Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements Launched XDEMVY® (lotilaner ophthalmic solution) 0.25%, for the treatment of Demodex blepharitis and generated fourth quarter net product sales of $13.1 million, and$14.7 million in the first four months since launch Delivered more than 17,400 bottles of XDEMVY to patients Continued pipeline execution – reported positive proof-of-concept results across entire clinical portfolio Management to host conf ...